Nektar Therapeutics (NKTR) Price & Analysis

Compare

1,482 Followers

NKTR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.49 - $37.38

Previous CloseN/A

Volume706.47K

Average Volume (3M)2.23M

Market Cap

$390.31M

Enterprise Value$111.46M

Total Cash (Recent Filing)$218.63M

Total Debt (Recent Filing)$100.34M

Price to Earnings (P/E)―

Beta3.73

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.95

Shares Outstanding17,301,062

10 Day Avg. Volume592,229

30 Day Avg. Volume2,226,615

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.29

Enterprise Value/Revenue1.28

Enterprise Value/Gross Profit1.71

Enterprise Value/Ebitda-1.14

Forecast

1Y Price Target

$95.80

Price Target Upside324.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe robust Phase 2b REZOLVE-AD trial confirmed REZPEG as a novel MOA with strong induction efficacy and clean safety on par with (if not better than) current market leaders in atopic dermatitis.

Financial StabilityNektar had cash and cash equivalents of approximately $221M, which is believed to be sufficient to fund operations into 4Q26.

Market PotentialA large attractive opportunity is seen for REZPEG to emerge as a valuable addition to the treatment landscape as a novel, broader and importantly, safe mechanism.

Bears Say

Clinical Data UncertaintyThe full data from the induction period are yet to be presented, leaving some uncertainty about the complete efficacy of the treatment.

Earnings ReportThe company reported revenue of $10.5M and a net loss of $0.24 per share, which was below consensus estimates.

Legal IssuesThe lawsuit initiated in 2023 by NKTR against LLY makes a compelling case that LLY misrepresented REZPEG's activity in atopic dermatitis and psoriasis, while contriving ISRs as a significant tolerability issue.

Nektar Therapeutics News

Nektar reports Q2 adjusted EPS ($2.78), consensus ($3.12)

Reports Q2 revenue $11.2M, consensus $9.42M. “This quarter, we announced transformative data for rezpegaldesleukin from the Phase 2b...

2h ago

NKTR

Nektar’s rezpegaldesleukin granted Fast Track Designation in alopecia areata

Nektar (NKTR) announced that the FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very...

9d ago

NKTR

Nektar call volume above normal and directionally bullish

Bullish option flow detected in Nektar (NKTR) with 8,409 calls trading, 3x expected, and implied vol increasing over...

21d ago

NKTR

Nektar call volume above normal and directionally bullish

Bullish option flow detected in Nektar (NKTR) with 4,070 calls trading, 1.3x expected, and implied vol increasing almost...

23d ago

NKTR

NKTR Upcoming Earnings Report: What to Expect?

Nektar Therapeutics (NKTR) is scheduled to report 2nd quarter earnings on 08/07/2025, after the market closes. Regarding Q2...

3d ago

NKTR

Nektar price target raised to $85 from $60 at B. Riley

B. Riley raised the firm’s price target on Nektar (NKTR) to $85 from $60 and keeps a Buy...

1M ago

NKTR

Nektar Therapeutics Announces Public Offering of Shares

Nektar Therapeutics ( ($NKTR) ) has shared an announcement. On June 30, 2025, Nektar Therapeutics announced an underwritten...

1M ago

NKTR

Nektar 4.255M share Spot Secondary priced at $23.50

The deal range was $23.00-$23.50. Jefferies and Piper Sandler acted as joint book running managers for the offering....

1M ago

NKTR

Nektar 4.255M share Spot Secondary priced at $23.00.50

The deal range was $23.00-$23.50. Jefferies and Piper Sandler acted as joint book running managers for the offering....

1M ago

NKTR

Closing Bell Movers: Progress Software slips 4% after earnings

In the opening hour of the evening session, U.S. equity futures are down marginally, with S&P500, Nasdaq 100...

1M ago

CXW

DYN

Nektar announces common stock offering, no amount given

Nektar (NKTR) Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock...

1M ago

NKTR

Nektar Therapeutics Regains Nasdaq Compliance by June 2025

Nektar Therapeutics ( ($NKTR) ) has shared an announcement. On April 3, 2025, Nektar Therapeutics was notified by...

1M ago

NKTR

Nektar Therapeutics’ Phase 2b Study on Rezpegaldesleukin: A Potential Game-Changer for Atopic Dermatitis

Nektar Therapeutics (($NKTR)), Nektar Therapeutics (($CC:NKTR.CUR)) announced an update on their ongoing clinical study. The recent clinical study...

1M ago

NKTR

Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?

Nektar Therapeutics stock soared on Tuesday after the company posted positive clinical trial results. ...

1M ago

NKTR

NKTR FAQ

What was Nektar Therapeutics’s price range in the past 12 months?

Nektar Therapeutics lowest stock price was $6.49 and its highest was $37.38 in the past 12 months.

What is Nektar Therapeutics’s market cap?

Nektar Therapeutics’s market cap is $390.31M.

When is Nektar Therapeutics’s upcoming earnings report date?

Nektar Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 91 days.

How were Nektar Therapeutics’s earnings last quarter?

Nektar Therapeutics released its earnings results on Aug 07, 2025. The company reported -$2.95 earnings per share for the quarter, beating the consensus estimate of -$3.028 by $0.078.

Is Nektar Therapeutics overvalued?

According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nektar Therapeutics pay dividends?

Nektar Therapeutics does not currently pay dividends.

What is Nektar Therapeutics’s EPS estimate?

Nektar Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nektar Therapeutics have?

Nektar Therapeutics has 17,301,062 shares outstanding.

What happened to Nektar Therapeutics’s price movement after its last earnings report?

Nektar Therapeutics reported an EPS of -$2.95 in its last earnings report, beating expectations of -$3.028. Following the earnings report the stock price went down -4.849%.

Which hedge fund is a major shareholder of Nektar Therapeutics?

Currently, no hedge funds are holding shares in NKTR

Nektar Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-189.46%

Trailing 12-Months

Asset Growth

-35.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, specializing in the development of innovative drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. The company leverages its proprietary PEGylation and polymer conjugate technology platforms to develop new therapeutics that aim to improve the efficacy and safety profile of existing drugs. Nektar's pipeline includes a range of investigational medicines, with a focus on oncology and immunology.

Nektar Therapeutics (NKTR) Earnings & Revenues

Historic Earnings Reports

NKTR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Nektar Therapeutics presented a quarter with significant advancements in their REZPEG studies and a strong financial position. However, the ongoing litigation with Lilly and non-cash losses from an equity investment present challenges.View all NKTR earnings summaries

NKTR Stock 12 Month Forecast

Average Price Target

$95.80

▲(324.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","121":"$121","36.25":"$36.3","64.5":"$64.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,36.25,64.5,92.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.59,31.92923076923077,39.26846153846154,46.607692307692304,53.94692307692307,61.28615384615384,68.62538461538462,75.96461538461539,83.30384615384615,90.64307692307692,97.98230769230769,105.32153846153845,112.66076923076923,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.59,30.067692307692308,35.54538461538461,41.02307692307692,46.50076923076923,51.97846153846154,57.45615384615384,62.93384615384615,68.41153846153846,73.88923076923076,79.36692307692307,84.84461538461538,90.32230769230769,{"y":95.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.59,28.006153846153847,31.42230769230769,34.83846153846154,38.254615384615384,41.67076923076923,45.08692307692307,48.50307692307692,51.919230769230765,55.33538461538461,58.75153846153846,62.167692307692306,65.58384615384615,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.7,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.75,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.05,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >